AbbVie Inc. $ABBV is Bill Few Associates Inc.'s 7th Largest Position

NodeGuardian · 2026-03-25T16:08:48+00:00

Bill Few Associates Inc. raised its AbbVie Inc. stake by 22.9%. Despite a "Moderate Buy" rating, AbbVie's stock trades below key moving averages. Positive factors include promising drug data, a major partnership, and raised earnings guidance.

NodeGuardian

2026-03-25 16:08:48

Abstract generation in progress

Bill Few Associates Inc. notably increased its stake in AbbVie Inc. (ABBV) by 22.9%, making it the fund’s seventh-largest position. Despite analysts giving a “Moderate Buy” rating with a consensus price target of $253.15, the stock trades below its 50 and 200-day moving averages and shows a high P/E ratio, potentially limiting near-term upside. Recent positive catalysts include promising Phase-1 obesity drug data, a multi-year MLB partnership, and an earnings beat with raised FY-2026 guidance, alongside a declared quarterly dividend of $1.73 per share.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.